Selinexor in combination with azacitidine or ruxolitinib in myelodysplastic/myeloproliferative neoplasm overlap syndromes: A multicenter prospective study - PubMed
4 hours ago
- #selinexor
- #combination therapy
- #MDS/MPN overlap syndromes
- Selinexor combined with azacitidine or ruxolitinib was evaluated in a prospective trial for MDS/MPN overlap syndromes.
- The overall response rate was 60% across 20 patients, with 75% in the MDS-dominant group and 56.3% in the MPN-dominant group.
- Clinical benefits included improvements in symptom scores, erythroid, platelet, and spleen responses in both groups.
- Adverse events occurred in 70% of patients, with three grade 3+ events including two disease-related fatalities.
- The combination showed encouraging efficacy and a manageable safety profile in MDS/MPN patients.